WEKO3
アイテム
A Novel Cancer Treatment Using Radiotherapy-Induced Autoantibodies: Overcoming the Limitations of Dendritic Cell Vaccine Therapy
https://repo.qst.go.jp/records/2002439
https://repo.qst.go.jp/records/20024398fa3317c-30d0-4960-bfd3-5ca14d09b541
| アイテムタイプ | 会議発表用資料 / Presentation(1) | |||||||
|---|---|---|---|---|---|---|---|---|
| 公開日 | 2025-11-12 | |||||||
| タイトル | ||||||||
| タイトル | A Novel Cancer Treatment Using Radiotherapy-Induced Autoantibodies: Overcoming the Limitations of Dendritic Cell Vaccine Therapy | |||||||
| 言語 | en | |||||||
| 言語 | ||||||||
| 言語 | eng | |||||||
| 資源タイプ | ||||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||||
| 資源タイプ | conference presentation | |||||||
| 著者 |
Takeshima Tsuguhide
× Takeshima Tsuguhide
|
|||||||
| 抄録 | ||||||||
| 内容記述 | Radiotherapy (RT) not only destroys tumor cells but also induces systemic antitumor immunity. These effects have motivated combining RT with immunotherapies to control local and distant disease. Immune checkpoint inhibitors (ICIs) can be effective, but they rely on pre-existing T cell immunity and often fail in poorly immunogenic tumors. As a form of immunotherapy, dendritic cell (DC) vaccine therapy can prime tumor-specific cytotoxic T lymphocytes (CTLs), but its efficacy is limited because injected DCs migrate poorly to draining lymph nodes, where CTLs are activated.We found that local X-ray irradiation markedly increased serum levels of radiotherapy-induced tumor-binding autoantibodies (TBA) in B16F10-OVA tumor–bearing mice. Based on this finding, we developed a novel approach using these TBA, collected from serum of irradiated mice, to enhance DC vaccine therapy. To our knowledge, this is the first study to utilize radiotherapy-induced autoantibodies for cancer treatment. Bone marrow–derived DCs (BMDCs), which can be generated in large numbers, were prepared, and TBA purified from irradiated mice were bound to their Fc receptors. We hypothesized that TBA–Fc receptor binding on BMDCs would enhance tumor antigen uptake and promote migration to draining lymph nodes.In the B16F10-OVA melanoma model, BMDCs bound with RT-induced TBA generated stronger CTL responses in lymph nodes and tumors, suppressed tumor growth more effectively than standard BMDC vaccination, and provided added benefit when combined with RT. This strategy links the immune-stimulating effects of RT with a personalized cancer vaccine platform and may complement or offer an alternative to ICI-based therapy. | |||||||
| 会議概要（会議名, 開催地, 会期, 主催者等） | ||||||||
| 内容記述 | 日本放射線影響学会第68回大会/第6回アジア放射線研究会議（JRRS/ACRR2025）合同大会 | |||||||
| 発表年月日 | ||||||||
| 日付 | 2025-10-26 | |||||||
